Ongoing business development is KEY for any growing business.

At Vizen, our specialised Business Development team are driven to identify opportunities for negotiation or acquisition of in-license and/or development stage products, covering a vast range of medicinal markets such as OTC & prescription medicines, medical devices, food supplements and cosmetics.

We offer our clients both a domestic and international service of technical and commercial expertise. As a result, our team have facilitated not only successful in/out licensing of products but also multiple successful EU product launches spanning the Pharmaceutical industry.

We will provide you with a complex strategy plan for market entry, including all EU countries, supplying you with the right form (private label) and arranging for tailor-made dossiers to be created or building on those that you have already started – focused on WEU and THMP (generics).

We will also deliver the complex market analysis utilising the latest IMS data. Helping to evaluate the molecular potential and offer advice on the preparation of dossiers, as well as arranging the comprehensive pre-registration due diligence and ventures activities.

Specialising in supporting the product lifecycle from research to pharmacy shelf.

Pharmaceutical consulting services are used by many pharmaceutical and biotech companies. Often they are looking for an expert team experienced in scientific and management leadership. If your company requires a team who can confidently manage the entire drug development programme – from research to the pharmacy shelf – then Vizen can provide the services you need.

We have great experience with product search, portfolio development to dossier compilation, contract manufacturing, registration and marketing of your product as required.

Commercializing on pharma innovation can be a challenge, especially in today's global markets where competition is fierce.

A pharmaceutical company's pipeline is regarded as its life blood and the compounds it contains are thought of as its crown jewels

However, there are two reasons that have surfaced in recent years that are helping to drive the increasing number of out-licensing deals now embraced by the industry:

1. The challenging environment that exists for developing a successful new product;
2. More highly constricted R&D budgets.

Vizen has in depth knowledge around Out-Licensing and how valuable it can be in the current climate. Speak to one of our experienced staff to get a better understanding of how we can help.

In-licensing is becoming more and more commonplace. In part, that's because of the influx of small biotechs on the market. These early stage companies are a key source of promising product candidates, which pharmaceutical companies then license certain rights to.

Licensing is cost-effective, since the financial burden of product development is shared. It's also lower risk for the company buying in: they can make deals based on promising pre-clinical or clinical results

We provide support for:

• Acquiring of RA dossiers
• Complex license purchasing from MA to contract manufacturing
• Dossier compilation tailored to your business plans
• Product search
• BD negotiations, legal advice